| Literature DB >> 25720462 |
Yohei Kosugi1, Syunsuke Yamamoto1, Noriyasu Sano1, Atsutoshi Furuta1, Tomoko Igari1, Yasushi Fujioka1, Nobuyuki Amano1.
Abstract
We attempted to establish animal models to evaluate the effects of drug degradation in the stomach on oral bioavailability. In addition, we assessed the utilization of animal studies in determining the need for enteric-coated formulations. In order to control the gastric pH in rats and dogs, appropriate dosing conditions were investigated using pentagastrin and rabeprazole, which stimulate and inhibit gastric acid secretion. Using animals controlled for gastric acid secretion, the area under curve (AUC) ratios (AUC with rabeprazole/AUC with pentagastrin) of all compounds unstable under acidic conditions were evaluated. The AUC ratios of omeprazole and erythromycin, which are administered orally to humans, as enteric-coated tablets, were greater than 1.9 in the rats and dogs controlled for gastric acid secretion. On the contrary, the AUC ratios of clarithromycin, azithromycin, and etoposide (commercially available as a standard immediate-release form) were less than 1.3 each. In conclusion, in vivo models using rats and dogs were optimized to evaluate the effects of gastric acid on the oral bioavailability of drugs, and demonstrated that in vivo models can lead to a better understanding of the oral bioavailability, with respect to the formulation development.Entities:
Keywords: acid tolerance; enteric coating; formulation; gastric acid secretion; gastric pH; oral bioavailability; pentagastrin; pharmacokinetics; stability
Mesh:
Substances:
Year: 2015 PMID: 25720462 DOI: 10.1002/jps.24401
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534